top of page

Research //

As Professor of Urology at UCL I lead a multidisciplinary research team. In 2021 I was awarded the prestigious Royal College of Surgeons of England Research Consultant Research fellowship. I am actively involved in clinical research and has published extensively. I maintain a strong academic interest and leads on several high profile research projects. Click here for my researchgate profile

I am  the Chief Investigator of the PROVENT clinical trial. This trial will evaluate the role of aspirin and vitamin D in preventing progression of indolent prostate cancer, to more sinister disease. The study is well received by men on active surveillance with a high rate of uptake by those who are eligible as it allows those men to feel that they are doing something rather than just waiting and seeing if their cancer will progress. This exemplifies my preference for doing surgery only when it is necessary. The feasibility phase of the study is now complete.

​

​

​

​

​

​

​

​

I am  Chief investigator for the NeuroSAFE PROOF study. This is funded through the National Institute for Health Research - Research for Patient Benefit scheme and the JP Moulton Foundation. The study is a randomised controlled study to evaluate a new technique called NeuroSAFE.

​

Prostate cancer is one of the most common cancers but can often be cured with surgery. Sadly, this sometimes leads to a loss of erections, because the nerves that bring about the erections run in the outer part of the prostate. A process known as nerve sparing, where the outer layers of the prostate are peeled off the prostate, increases the chance of men being potent after surgery. On the other hand, nerve sparing increases the risk of cancer being left behind. Any cancer left behind will need more treatment with radiotherapy that will leave men without the ability to achieve erection, even if they had nerve-sparing surgery.

 

The prostate is enclosed by a capsule that contains smooth muscle and nerves. Many men having their prostates removed have cancer that extends through the capsule of the prostate. Currently, there isn’t a good way of knowing whether the cancer has spread through the capsule of the prostate and the accuracy of scans like MRI in detecting capsular involvement is limited. Nerve sparing surgery in these patients can cause some cancer to be left behind. A new technique called NeuroSAFE technique may address this problem. It includes a step where a doctor looks at the prostate near where the nerves were, to check for exposed cancer. If cancer is found at the edge of the prostate, the nerve tissue is removed so the chance of the cancer coming back is the same as when cancer cells are not exposed.

 

We are now actively recruiting to a  large-scale trial where NeuroSAFE will be compared with the current UK practice for prostate cancer (nerve sparing based on an MRI scan, biopsy results and the way the prostate feels).

Provent prostate cancer study logo
dNeuroSAFE Proof prostate cance study logo
Publications //

  1. The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metaststatic prostate cancer- frontiers oncology 2022

  2. Prostate Cancer (a review), Almeida R, Accepted for publication, Surgery, Sept 2022

  3. Neurosafe proof: study protocol for a single blinded, IDEAL stage 3, multi-centre, randomised controlled trial of NEUROSAFE robotic- assisted radical prostatectomy versus standard robotic-assisted radical prostatectomy in men with localized prostate cancer. E Dinneen, …. Accepted Trials , 2022

  4. Feasibility of aspirin and/or Vitamin D3 for men with prostate cancer on active surveillance with Prolaris testing, E Dinneen, …, , J Cusick, Accepted BJUI Compass, 2022

  5. Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer. Luszczak S, … .. Heavey S. Sci Rep. 2020 Sep 1;10(1):14380 PMID: 32873828

  6. E-Consent – a guide to maintain recruitment in clinical trials during the COVID-19 pandemic. R Almeida-Magana … Accepted for publication BMC Trials 2022

  7. Negative mpMRI rules out extra-prostatic extension in prostate cancer before robot-assisted radical prostatectomy. E Dinneen…. *, S Punwani* Diagnostics 2022 (* denotes equal contribution)

  8. Avoiding unnecessary biopsy after multiparametric prostate MRI with VERDICT analysis:  the INNOVATE study. S Singh, ..… S Punwani accepted Radiology 2021

  9. Histo-MRI map: A prospective cohort study mapping MRI to histology for biomarker validation and prediction of prostate cancer. S Singh,.., ,…,D Alexander, S Punwani BMJ Open Accepted 2022

  10. Current process and outcomes of the surgical management of LUTS due to benign prostatic enlargement – Results from the national Audit of Surgical Management of BPE (AuSuM BPE). by Joshi, Hr.. Shaw, Greg; .. Betts, Chris Scottish journal or Urology 2021 May;66(2):58-65 2021 PMID 33459189

  11. Re: Bernardo Rocco, Luca Sarchi, Simone Assumma et al.Digital Frozen Sections with Fluorescence Confocal Microscopy During Robot-assisted Radical Prostatectomy: Surgical Technique. European Urology 2021 May 5;S0302-2838(21)00227-X.  doi: 10.1016/j.eururo.2021.03.021.   E Dinneen, J Oxley, G Shaw, and on behalf of the NeuroSAFE PROOF Team. European Urology 2021.

  12. Comparative effectiveness analysis of oncological and functional outcomes after salvage radical treatment with surgery or radiotherapy following primary focal or whole-gland ablative therapy for localised prostate cancer. A Nathan., .,.H Payne Clinical Oncology 2021

  13. New recommendations to reduce unnecessary blood tests following robot assisted radical prostatectomy. A Nathan ,… .. , S Nathan  BJU Int 2021 Jun 10. PMID: 34110673

  14. Inter-reader agreement of the PI-QUAL score for prostate MRI quality in the NeuroSAFE PROOF trial, F Giganti, .., et al. European Radiology Accepted 2021 PMID 34327583

  15. Evaluation of the Multiparametric Magnetic Resonance Imaging-Directed Diagnostic Pathway for Suspected Prostate Cancer: Diagnostic Outcomes and Prostate Specific Antigen and Prostate Specific Antigen Density Values from the INNOVATE Trial H Pye, S Singh,.. , ..H Whitaker accepted Cancers 2021 PMID 33924255

  16. Salvage Versus Primary Robot-assisted Radical Prostatectomy: A Propensity-matched Comparative Effectiveness Study from a High-volume Tertiary Centre Nathan A.., , …Nathan S Eur Urol Open Science 2021 PMID 33997823

  17. Life of Pi- E Dinneen & BJU Int. 2020 Dec;126(6):754-755. PMID: 33270968

  18. Tandogdu Z.. … Kelly J. Management of patients who opt for radical prostatectomy during the COVID-19 pandemic: An International Accelerated Consensus view. BJU Int. 2020 Nov 13. PMID: 33185026

  19. Major urological cancer surgery for patients is safe and surgical training should be encouraged during the COVID-19 pandemic: A multi-centre analysis of 30-day outcomes. Wei Shen Tan et al. Collaborator. Eur Urol Open Sci. 2021 Mar;25:39-43. PMID: 33458711

  20. The identification of plasma exosomal miR-423-3p as a potential predictive biomarker for prostate cancer castration-resistance development by plasma exosomal miRNA sequencing. Tianyu Guoa..et al. Front Cell Dev Biol. 2021 Jan 7;8:602493. PMID: 33490068

  21. A cohort study of 30 day mortality after NON-EMERGENCY surgery in a COVID-19 cold site. A cohort study of 30 day mortality after NON-EMERGENCY surgery in a COVID-19 cold site. Kasivisvanathan, V...Wood, C. . International Journal of Surgery, 2020, 84, pp. 57-65 PMID: 33122153

  22. NeuroSAFE frozen section during robot-assisted radical prostatectomy (RARP): Peri-operative and Histopathological Outcomes from the NeuroSAFE PROOF Feasibility Randomised Controlled Trial. Eoin Dinneen, ..J Grierson, A Haider, A Freeman, and . BJU Int. 2020 Sep 27. PMID: 32985121

  23. Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer L Li , .., , .. M Ladomery et al. Br J Cancer. 2020 Sep;123(6):1024-1032. PMID: 32581342

  24. Digital frozen section of the prostate surface during radical prostatectomy: a novel approach to evaluate surgical margins. B Rocco , ..G Shaw, S Nathan, S Micali , G Bianchi, A Maiorana , G Pellacani, R Montironi  BJU Int, 2020 Sep;126(3):336-338.  PMID: 32401370

  25. NeuroSAFE Technique - pathological considerations and practical implications to guide nerve-sparing surgery in prostate cancer patients. E Dinneen, A Hayder, , Histopathology. 2020 Oct;77(4):536-538. PMID: 32945017

  26. NeuroSAFE PROOF Randomised Controlled Feasibility Study:Brief Report of Perioperative outcomes, histological concordance and feasibility. E Dinneen, , Eur Urol. 2020 Sep;78(3):476-478. PMID: 32340693

  27. Intraoperative Frozen Section for margin evaluation during Radical Prostatectomy: A Systematic Review. Eoin Dinneen, MIchelle van der Slot, Kelvin Adasonla, Jin Tan, Jack Grierson, Aiman Haider, Alex Freeman, and Eur Urol Focus. 2019 Nov 29. PMID: 31787570

  28. Re: Non-invasive detection of clinically significant prostate cancer using circulating tumor cells. Xu L, Mao X, Grey A, Scandura G, Guo T, Burke E, Marzec J, Abdu S, Stankiewicz E, Davies CR, Rajan P, Tipples K, Hines J, Chan PY, Campbell D, Wilkinson K, Kudahetti S, Shamash J, Oliver T, Berney D, Lu YJ. Reply by Authors. Journal of Urology, vol. 203, no. 1, 2020, pp. 73-82.

  29. Use of Magnetic Resonance Imaging (MRI) and biopsy data to guide sampling procedures for prostate cancer biobanking. S Heavey, A Haider, A Sridhar, H Pye, , A Freeman, H Whitaker. J Vis Exp. 2019 Oct 10;(152). PMID: 31657791

  30. Thompson JE, …, et al. Pathological Findings and Magnetic Resonance Imaging Concordance at Salvage Radical Prostatectomy for Local Recurrence following Partial Ablation Using High Intensity Focused Ultrasound. J Urol. 2019;201(6):1134-43.

  31. Re:”What is the role of NeuroSAFE in robotic radical prostatectomy?” Journal of Robotic surgery. Dinneen E,.. J Robot Surg. 2019 Oct;13(5):707-708. PMID: 30980228

  32. Massive Ascites Following Robot-Assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: A Case Report Ahmed S, , Alkadhi O 27 Jun 2019 https://doi.org/10.1089/cren.2018.0080

  33. Dinneen E, Haider A, Allen C, Freeman A, Briggs T, Nathan S, Brew-Graves C, Grierson J, Williams NR, Persad R, Oakley N, Adshead JM, Huland H, Haese A, . NeuroSAFE robot-assisted laparoscopic prostatectomy versus standard robot-assisted laparoscopic prostatectomy for men with localised prostate cancer (NeuroSAFE PROOF): protocol for a randomised controlled feasibility study. BMJ Open. 2019 Jun 11;9(6):e028132. PMID:31189680

  34. PEOPLE: PatiEnt prOstate samPLes for rEsearch, a tissue collection pathway utilising MRI data to target tumour and benign tissue in fresh radical prostatectomy specimens. Heavey S, .., , et al. Prostate. 2019 May;79(7):768-777. PMID: 30807665

  35. C Bailey, RM Bourne, B Siow, EW Johnston, M Appayya.. , A Sridhar, DJ Hawkes, S Punwani, DC Alexander, E Panagiotaki VERDICT MRI validation in fresh and fixed prostate specimens using patient-specific molds for histological and MR alignment. NMR in Biomedicine. In press 2019

  36. Dutto L, Ahmad A, Urbanova K, Wagner C, Schuette A, Addali M, Kelly J.D, Sridhar A, Nathan S, Briggs T.P, Witt J. H, Development and validation of a novel risk score for the detection of insignificant prostate cancer in unscreened patient cohorts. British Journal of Cancer 2018 119, 1445–1450

  37. A. Warren, C. Massie, .., .. M Asim Feedback between the PDZ binding kinase and androgen receptor drives prostate cancer. Oncogene.2018 Sep 20 PMID:30237440. Oncogene, 2018

  38. T. Oliver, P.Wilson, W, Ansell, T, Philp, F. Chinegwundoh, J. Shamash, A prospective audit of intermittent anti-androgen verses pituitary blockade suggests a Bipolar Androgen type strategy may be safe in untreated Prostate Cancer. Urol Int. 2017 Dec 22. PMID: 29275414.

  39. AN Sridhar, M Abozaidi, P Rajan, P Sooriakumaran, , S Nathan, JD Kelly, T Briggs Surgical Techniques to Optimize Early Urinary Continence Recovery Post Robot Assisted Radical Prostatectomy for Prostate Cancer. Curr Urol Rep (2017) 18: 71 PMID: 28718165

  40. Learning curves for robotic surgery: a review of the recent literature. Mazzon G, Sridhar A, Busuttil G, Thompson J, Nathan S, Briggs T, Kelly J, , Curr Urol Rep. 2017 Sep 23;18(11):89. Review. PubMed PMID: 28942572.

  41. Asim M. Zecchini HI, Massie CE, ,.. Neal DE. Synthetic Lethality between Androgen receptor signaling and PARP pathway in Prostate Cancer. Nat Commun. 2017 Aug 29;8(1):374. PMID: 28851861

  42. Xu L, Mao X, Guo T, Chan PY, , Hines J, Stankiewicz E, Wang Y, Oliver T, Ahmad A, Berney D, Shamash J, Lu YJ. The novel association of circulating tumor cells and circulating megakaryocytes with prostate cancer prognosis Accepted Clinical Cancer Research 2017 Sep 1;23(17):5112-5122. PMID: 28615267.

  43. Bourne RM, Bailey C, Johnston EW, Pye H, Heavey S, Whitaker H, Siow B, Freeman A, , et al. Apparatus for Histological Validation of In Vivo and Ex Vivo Magnetic Resonance Imaging of the Human Prostate. Front Oncol. 2017 Mar 24;7:47. PubMed PMID: 28393049

  44. Tan W,.., Kelly JD Blood Transfusion Requirement and not Preoperative Anaemia is associated with Perioperative Complications following Intracorporeal Robotic Assisted Radical Cystectomy. J Endourol. 2017 Feb;31(2):141-148. PMID: 27901350.

  45. Johnston T, , Donovan J, Hamdy F, Neal DE, PSA screening improves outcome for men with locally advanced and high risk prostate cancer. Data from the ProtecT trial. European Urology 2017 Mar;71(3):381-388 (In the top 5% of all research outputs scored by Altmetric)

  46. Tan WS, Lamb B, Tan MY, Ahmad I, Sridhar A, Nathan S, Hines J, , Briggs T, Kelly J. An in depth critical analysis of complications following robotic assisted radical cystectomy with intracorporeal urinary diversion. Eur Urol Focus. 2017 Apr;3(2-3):273-279. PMID: 28753745.

  47. Basetti M, Neal D, Warren A, Griffiths J. Response of Degarelix treatment in human prostate cancer monitored by HR-MAS1H NMR spectroscopy. Metabolomics (2016) 12:120 PMID: 27429605

  48. D Thurtle, , V Gnanapragasam. Evolution and oncological outcomes of a contemporary radical prostatectomy practice in a UK regional tertiary referral centre. BJU Int. 2016 Apr 28.PMID 27124625

  49. Shaw GL, Whitaker H, Corcoran M, Warren A, Neal DE, The rapid effects of castration on human prostate cancer. Eur Urol. 2015 Nov 10 PMID: 26572708

  50. Ross-Adams H, Lamb AD, et al. CamCaP Study Group. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery andvalidation cohort study. EBioMedicine. 2015 Jul 29;2(9):1133-44. PMID: 26501111.

  51. Vasdev N, Agarwal S, Rai BP, Soosainathan A, , Chang S, Prasad V, Mohan-S G, Adshead JM. Intraoperative frozen section of the prostate to reduces the risk of positive margin whilst ensuring nerve sparing in patients with Intermediate and high-risk prostate cancer undergoing robotic radical prostatectomy – First Reported UK Series. Curr Urol. 2016 May;9(2):93-103. PMID: 27390582

  52. Asim M, Massie C, Orafidiya F, and Neal DE. Choline kinase alpha is an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. J Natl Cancer Inst. 2015 Dec 11;108(5). 2016 May. PMID:26657335

  53. Thomas BC, Kay JD, Menon S, Vowler SL, Dawson SN, , Neal DE, Whitaker HC. Whole blood mRNA in prostate cancer reveals a 4-gene androgen regulated panel. Endocrine related cancer 2016 Oct;23(10):797-812. PMID: 27578825.

  54. Pertega-Gomes N, Vizcaino JR , Felisbino S, Warren AY, , Fryer L, Neal DE and Massie CE. MCT2 protein over-expression throughout prostate cancer progression impacts on oncogenic signaling and malignant phenotypes. Oncotarget 2015 Jun 2. PMID:26035357

  55. Shaw GL, Thomas B, Dawson S, Srivastava G, Vowler S, Gnanapragasam V, Shah N, Warren A, Neal D. Identification of pathologically insignificant prostate cancer is not accurate in unscreened men. Br J Cancer. 2014 May 13;110(10):2405-11. PMID: 24722183

  56. Sooriakumaran P, Srivastava A, Shariat SF, Roobol MJ, Tewari AK Multinational, Multi-institutional Study Comparing Positive Surgical Margin Rates Among 22,393 Open, Laparoscopic, and Robot-assisted Radical Prostatectomy Patients. Eur Urol. 2013 Nov 24. PMID: 24290695.

  57. Lewis D, Boren J, , Bielik R, Ramos-Montoya A, Larkin T, Martins C, Neal DE, Soloviev D, Brindle K. Late imaging with [1-11C]acetate PET improves tumour contrast. J Nucl Med. 2014 Apr 28, PMID: 24777291.

  58. A.Ramos-Montoya, A Lamb, R. Russell, V. Theodorou, J. Boren, H.Bon, M.Vias, , N.L Sharma, H.E Scott, SL Vowler, T Carroll, CE Massie, WJ Howat, AY Warren, R. Wooster,I Mills, D.E. Neal. HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network. EMBO Mol Med. 2014 May 1;6(5):651-61. PMID: 24737870

  59. Shaw GL. Science made simple- Polymorphism- RFLPs and SNPs, BJU International 09/2013; 112(5).

  60. Shaw GL, Hussain M, Nair R, Bycroft J, Beltran L, Green JS, Powles T, Peters JL, Performing cytoreductive nephrectomy following targeted Sunitinib therapy for metastatic renal cell carcinoma- a surgical perspective Urol Int. 2012;89(1):83-8.. PMID: 22614181.

  61. Gnanapragasam V, , Mason M, Neal D, Optimal therapy for high risk localised prostate cancer - should surgery be an option or a preferred primary treatment? BJU Int. 2011 Sep 27. doi: 10.1111/j.1464-410X.2011.10596.x. PMID: 21951841

  62. Boyd L, Xue L, Mao X, Li D, Beltran L, , Hines J, Chaplin T, Berney DM, Bryan D. Young BD, Lu YJ. High-resolution genome-wide copy-number analysis suggests a monoclonal origin of multi-focal prostate cancer. Genes Chromosomes Cancer. 2012 Jun;51(6):579-89. PMID: 22334418.

  63. Rouse P, , Ahmed H, Freeman A, Allen C, Emberton M. Multi-parametric Magnetic Resonance Imaging to rule-in and rule-out clinically important prostate cancer in men at risk: a cohort study. Urol Int. 2011;87(1):49-53. PMID: 21701136

  64. Vasiljević N, Wu K, Brentnall A, Kim DC, Thorat MA., Kudahetti S, Mao X, Xue L, Yu Y, , Beltran L,. Lu YJ, Berney D, Cuzick J and Lorincz AT.Absolute Quantitation of DNA Methylation of 28 Candidate Genes in Prostate Cancer using Pyrosequencing. Dis Markers. 2011;30(4):151-61 2011. PMID: 21694441

  65. Shaw GL, Nair R, Peters J. Minerva, BMJ 2010;341:c3525

  66. Shaw GL, Ioannou I, Gelister J, Briggs T. Management of Vesico Urethral Anastamosis Disruption after Radical Prostatectomy. Urol Int  84, No. 4,  pp 436-439, 2010, PMID: 20224267

  67. Nair R, Holdroyd D, , Gelister J. Reducing false passages: a novel technique for difficult urethral catheterization. Ann R Coll Surg Engl 2010; 92: 259, PMID: 20425888

  68. Tuffaha H, , Briggs T. Augmented bladder appearance under blue light, J Endourol. Journal of Endourology. June 2010, 24(6): 943-944. PMID: 20367243

  69. Dukic I, , Hussein M, Maraj B. A comparison of handwritten to computerised urological operative notes. Brit J. Med Surg Urol..(2010) 3,22-24

  70. Shaw GL  and Bunce C. Fluorescence Cystoscopy- How to do it. Photodiagnosis and Photodynamic Therapy. (2008) 5, 267—270 PMID:19356669

  71. Shaw GL., Emberton M.E, Morgan R,  Berney D., Cuzick J, Oliver R.T.D. Patient designed therapy provides possible “natural” selection evidence for testosterone as differentiating agent for high grade prostate cancer. Brit J. Med Surg Urol. 2009 July 2 (4) 171-173.

  72. Shaw GL and Oliver RTD. Intermittent hormone therapy and its place in the contemporary endocrine treatment of prostate cancer.  J Surg Onc. Mar 2009 PMID:19269165

  73. Ahmed HU, Ishaq A, Zacharakis E, , Illing R, Allen C, Kirkham A,Emberton M. Rectal fistulae after salvage high-intensity focused ultrasound for recurrent prostate cancer after combined brachytherapy and external beam radiotherapy. BJU Int. 2008 Nov 18. 321-3 PMID:19021611

  74. Shaw GL and Prowse DM. Inhibition of androgen independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signaling Cancer Cell Int. 2008 Mar 18;8:3. PMID:18348720

  75. Shaw GL, Ktori E, Price AM, Bisson I,  Purkis P, McFaul S, Oliver RTD and  Prowse DM. Hedgehog Signalling in Androgen Independent Prostate Cancer. European Urology 2008 Dec;54(6):1333-43. PMID:18262716

  76. Mao X, , James SY, Purkis P, Kudahett SK, Tsigan T, Kia S, B Young BD, Oliver RTD, Berney D, Prowse DM and Lu YJ. Detection of TMPRSS2:ERG fusion gene in circulating prostate cancer cells. Asian Journal of Andrology 2008 May;10(3):467-73. PMID:18385909

  77. Shaw GL and Patel HRH. Transdermal Oxybutynin: a review. Expert Opinion in Pharmacology 2007 Jun;3(3):435-9. PMID: 17539749

  78. Shaw GL, Wilson P, Cuzick J, Prowse DM, Goldenberg SL, Spry N, Oliver RTD. International study into the use of intermittent therapy in the treatment of carcinoma of the prostate (ISICAP), a meta-analysis of 1446 patients. BJUi 2007 May;99(5):1056-65. PMID: 17346277 Cited as a highlight of Urology. Framingham on Urology. Issue 2 2007

  79. Shaw GL, Purkiss T, Oliver RT, Prowse DM. Re: Christine McKillop. Interview with Jack Schalken: PCA3 and its Use as a Diagnostic Test in Prostate Cancer. Eur Urol 2006;50:153-4. PMID:17049717

  80. Shaw GL., Wah TM, Kellett M, Choong S.: Management of renal-vein perforation during a challenging percutaneous nephrolithotomy. J Endourol, 19: 722, 2005 PMID:16053363

  81. Symes A, , Corry, D, Choong S.: Pelvi-calyceal height, a predictor of success when treating lower pole stones with extracorporeal shockwave lithotripsy. Urol Res, 33: 297, 2005 PMID:15937708

  82. Shaw GL, Choong SK, and Fry C.: Encrustation of biomaterials in the urinary tract. Urol Res, 33: 17, 2005  PMID:15614579

  83. Khan MA, , and Paris AM.: Is microscopic haematuria a urological emergency? BJU Int, 90: 355, 2002 PMID 12175388

  84. Martin JE. and .: Phenotype analysis in neurological models of human disease. Neuropathol Appl Neurobiol, 24: 83, 1998 PMID 9634201

  85. Jones M, , Roberts G, Sharaf A: Pre-hospital treatment of acute myocardial infarction by GPs: Audit trends,4: 91-94. 1996

Book an appointment //

For further advice on urological problems including cancer, please call us on +44 07841034453 to book an appointment, with Mr. Greg Shaw at his private clinic in London. Alternatively, contact us online.

bottom of page